Listen
Reason for request
Renewal of inclusion on the list of medicines refundable by National Health Insurance and re-assessment of Actual Benefit at the request of the Transparency Committee in accordance with article R 163-21 of the Social Security Code.
-
Clinical Benefit
| Moderate |
The actual benefit of this medicinal product remains moderate for treatment not exceeding 3 days. |
| Substantial |
The actual benefit of these medicinal products remains substantial in the Marketing Authorisation indications (exacerbations of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis). |
| Insufficient |
The actual benefit of this medicinal product remains is insufficient for treatment exceeding 3 days. |
Documents
English version
Contact Us
Évaluation des médicaments
